公开(公告)号：US20060171937A1

公开(公告)日：2006-08-03

申请号：US11398989

申请日：2006-04-05

申请人： Brett Giroir ,  Patrick Scannon

发明人： Brett Giroir ,  Patrick Scannon

IPC分类号： A61K38/43

CPC分类号： A61K38/1751

摘要： New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.

公开(公告)号：US20050054117A1

公开(公告)日：2005-03-10

申请号：US10660301

申请日：2003-09-10

申请人： Brett Giroir ,  Monty Willis ,  Timothy Church

发明人： Brett Giroir ,  Monty Willis ,  Timothy Church

IPC分类号： G01N33/68 ,  G01N33/543

CPC分类号： G01N33/6893 ,  G01N2800/32

摘要： Macrophage migration inhibitory factor (MIF) is a clinically useful biochemical marker of cardiovascular risk. Risk assessment includes the step of detecting in the blood of a person MIF concentration as a marker of cardiovascular risk for the person. The method may further comprise the step of assigning to the person a cardiovascular risk metric proportional to the MIF concentration, and/or prescribing for the person a cardiovascular treatment modality in accordance with the MIF concentration. The method is useful as a primary screen, and may be used in conjunction with or as a substitute for additional tests, such as a stress test, CRP assay, LDL assay, etc. The detecting step may be repeated over time intervals and/or treatment to monitor change in cardiovascular risk for the person over time and/or treatment.

摘要翻译： 巨噬细胞迁移抑制因子（MIF）是临床上有用的心血管风险生化标志物。 风险评估包括检测人血液中MIF浓度作为人心血管风险的标志物的步骤。 该方法可以进一步包括向人们分配与MIF浓度成比例的心血管风险度量，和/或根据MIF浓度向患者分配心血管治疗方式的步骤。 该方法可用作主要屏幕，并且可以与附加测试结合使用或代替其他测试，例如压力测试，CRP测定，LDL测定等。检测步骤可以随时间间隔和/或 治疗以监测随时间和/或治疗的人的心血管风险变化。

公开(公告)号：US20050202010A1

公开(公告)日：2005-09-15

申请号：US10927494

申请日：2004-08-27

申请人： Brett Giroir ,  Monte Willis ,  Vidal De La Cruz ,  Thais Sielecki-Dzurdz

发明人： Brett Giroir ,  Monte Willis ,  Vidal De La Cruz ,  Thais Sielecki-Dzurdz

IPC分类号： A61K20060101 ,  A61K39/395 ,  C07K16/24 ,  C07K16/28

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K16/2833 ,  C07K2317/76

摘要： One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.

摘要翻译： 本发明的一个实施方案涉及药物组合物，其包含治疗有效量的至少一种抗MIF抗体; 和至少一种药学上可接受的载体。 本发明的另一个实施方案涉及药物组合物，其包含治疗有效量的至少一种抗CD74抗体; 和至少一种药学上可接受的载体。 本发明的另一个实施方案涉及药物组合物，其包含治疗有效量的至少一种抗TNFR抗体; 治疗有效量的至少一种抗MIF抗体; 和至少一种药学上可接受的载体。 本发明的其它实施方案涉及治疗或预防心脏功能障碍，心脏抑制，烧伤相关心脏功能障碍，改善急性心肌梗死后受试者心脏功能以及鉴定MIF抑制剂的方法。